Finance and funding: latest news

Finance and funding features

Finance and funding news from aidsmap

More news

Finance and funding news selected from other sources

  • How Will Generic Drugs Affect HIV Treatment in the U.S.?

    In the U.S., in that many of the antiretroviral drugs that are commonly used today are approaching their patent expirations. So we can begin to conceptualize the use of generics in the U.S. and the potential cost savings. An Interview With Treatment Action Group's Tim Horn.

    8 hours ago | The Body
  • Elton John AIDS Foundation Invests in MSM, LGBT Programs

    The Elton John AIDS Foundation is joining PEPFAR and HRC to fund HIV programs focused on the U.S. LGBT population and South African men who have sex with men.

    8 hours ago | Poz magazine news
  • GSK eyes prime FTSE 100 slot for standalone HIV drugs business

    GlaxoSmithKline, battered by weak U.S. drug sales and a bribery scandal in China, is looking to float ViiV, its fast-growing HIV drugs business as part of a recovery plan that includes a fresh round of cost cutting.

    26 October 2014 | Reuters
  • 2014 Report on Tuberculosis Research Funding Trends, 2005–2013

    Worldwide, governments, foundations, and companies invested US$676.7 million in research to develop new drugs, vaccines, and diagnostics against tuberculosis (TB) in 2013—barely one-third of the US$2 billion that experts estimate the world must spend each year to end the global TB epidemic—according to an analysis released today by Treatment Action Group (TAG).

    22 October 2014 | TAG
  • IDWeek 2014: Behavioral and Financial Incentives May Improve HIV Treatment Outcomes

    While making medications free can remove barriers to access for individuals who cannot pay for treatment, data suggest that for most people accessing care in industrialized countries, "making medications available for free or low cost will not solve problems with medication non-adherence," according to a presentation by Kevin Volpp from the University of Pennsylvania last week at IDWeek 2014 in Philadelphia.

    16 October 2014 |
  • Unique 'pay if you clear' proposal for new hepatitis drug

    The NHS in Scotland could be reimbursed for the cost of a new hepatitis drug if sufferers fail to clear the virus. The novel proposal was revealed after the drug Olysio was cleared for use by the Scottish Medicines Consortium (SMC).

    15 October 2014 | BBC
  • Fair Pricing Coalition Urges a Uniform Price for Curative Hepatitis C Treatment

    The $63,000 wholesale acquisition cost (WAC) for eight weeks of Harvoni™ (sofosbuvir and ledipasvir) should be extended to 12 and 24-week curative treatment durations.

    15 October 2014 | Fair Pricing Coalition
  • As Hepatitis Pill Harvoni Joins Sovaldi, States Erect Medicaid Hurdles

    As Gilead Sciences launches its next generation Hepatitis C pill, Harvoni, Medicaid programs are bracing for another extraordinary wave of costs, with 70 percent of states implementing coverage restrictions.

    10 October 2014 | Forbes
  • Sovaldi ‘unaffordable’ says NHS documents

    Senior health officials may have to bar Gilead’s new hepatitis C pill Sovaldi from being funded on the NHS after new data shows it would cost the health service £1 billion a year to fund.

    08 October 2014 | Pharmafile
  • How Some State Medicaid Programs Limit Drugs to Only the Sickest Patients

    Because of its high cost, some state Medicaid programs and prison systems are refusing to provide Sovaldi to any but the sickest patients. Most recently, Oregon last month threatened to limit access to the drug unless it can get Sovaldi at a deeply discounted price. What can states do to hold down drug costs? Drug pricing is a complicated and opaque process. Here are some of the basics.

    07 October 2014 |
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.